The Union Health Ministry on Thursday, 17 September 2026, issued a formal advisory to regulate stem cell therapy across India, clarifying that the treatment may be offered as standard clinical care only for disease conditions explicitly approved by the Health Ministry. The advisory, dated 16 September, has been dispatched to all states and Union Territories that have adopted the Clinical Establishments (Registration and Regulation) Act, 2010.

What the Advisory Stipulates

The advisory reiterates the existing regulatory framework governing stem cell research and therapy in India. Stem cell therapy is permitted as routine standard care solely for indications on the Ministry's approved list. For all other conditions, its use must be restricted to duly approved clinical trials conducted under the National Guidelines for Stem Cell Research, 2017.

A specific provision addresses Autism Spectrum Disorder (ASD): the therapeutic use of any type of stem cell for autism is to remain confined to approved clinical trials only, with no scope for offering it as standard care outside that framework.

Legal Backing: Supreme Court and NMC Directives

The advisory draws its force from a Supreme Court judgment dated 30 January 2026, which held that non-compliance with the statutory mandate must attract consequences. These include professional misconduct under Regulation 7.22 of the IMC Regulations, 2002, and action under Sections 32 and 40 of the Clinical Establishments Act — provisions that allow for cancellation of registration and financial penalties.

Separately, the National Medical Commission (NMC) has also issued its own advisory reiterating that stem cell therapy may be offered as standard clinical care only for approved indications. The NMC has explicitly stated that unauthorised administration, prescription, promotion, or advertisement of stem cell therapy beyond approved indications will constitute professional misconduct.

Action Against Violations

'The Ministry has accordingly requested the concerned state and District Regulatory Authorities and clinical establishments to ensure strict compliance with the applicable framework governing stem cell research and therapy,' according to the official statement.

The NMC has further advised State Medical Councils to examine all cases of alleged violations brought to their notice. Where professional misconduct by a Registered Medical Practitioner is established after due process, councils are directed to take appropriate disciplinary action under the applicable statutory and regulatory provisions.

Why This Advisory Matters

Stem cell therapy has been a grey area in Indian clinical practice, with several private establishments reportedly offering it for unapproved conditions — including neurological disorders — at high cost to patients and families. This advisory closes a compliance gap by formally linking the existing legal framework to on-the-ground enforcement, particularly through state and district bodies that oversee registered clinical establishments. Notably, the advisory does not introduce new rules but reinforces and amplifies regulations that were already in place, suggesting authorities believe compliance has been inadequate.

With the Supreme Court's January 2026 ruling now explicitly cited as the enforcement anchor, practitioners and establishments operating outside approved indications face significantly higher legal exposure going forward.